New vaccine aims to tackle two viruses behind hand, foot, and mouth disease
NCT ID NCT06063057
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This clinical trial tested a new vaccine designed to protect against two viruses (EV71 and CA16) that cause hand, foot, and mouth disease and herpangina. The study involved 744 healthy adults and children, including kids as young as 6 months. Researchers checked the vaccine's safety and how well it triggers an immune response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Bivalent Enterovirus Vaccine (Vero Cell), Inactivated
- What this could lead to
- If successful, this vaccine could help prevent hand, foot, and mouth disease and herpangina caused by two common viruses (EV71 and CA16).
- What could go wrong
- This is an early-phase trial (Phase I/II) focused on safety and immune response, not yet proven to prevent disease. Results may not lead to a licensed vaccine.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HAND, FOOT AND MOUTH DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dayao County Center for Disease Control and Prevention
Chuxiong, Yunnan, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.